ATE342065T1 - Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant - Google Patents

Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant

Info

Publication number
ATE342065T1
ATE342065T1 AT00906305T AT00906305T ATE342065T1 AT E342065 T1 ATE342065 T1 AT E342065T1 AT 00906305 T AT00906305 T AT 00906305T AT 00906305 T AT00906305 T AT 00906305T AT E342065 T1 ATE342065 T1 AT E342065T1
Authority
AT
Austria
Prior art keywords
sub
adjuvant
fatty acids
monoglycerides
vaccine formulation
Prior art date
Application number
AT00906305T
Other languages
English (en)
Inventor
Ulf Schroeder
Stefan Svenson
Original Assignee
Eurocine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine Ab filed Critical Eurocine Ab
Application granted granted Critical
Publication of ATE342065T1 publication Critical patent/ATE342065T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00906305T 1999-02-12 2000-02-09 Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant ATE342065T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900495A SE9900495D0 (sv) 1999-02-12 1999-02-12 Vaccine composition

Publications (1)

Publication Number Publication Date
ATE342065T1 true ATE342065T1 (de) 2006-11-15

Family

ID=20414469

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00906305T ATE342065T1 (de) 1999-02-12 2000-02-09 Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant

Country Status (10)

Country Link
US (1) US6936260B1 (de)
EP (1) EP1154792B1 (de)
AT (1) ATE342065T1 (de)
AU (1) AU769390B2 (de)
DE (1) DE60031243T2 (de)
DK (1) DK1154792T3 (de)
ES (1) ES2275495T3 (de)
NZ (1) NZ513130A (de)
SE (1) SE9900495D0 (de)
WO (1) WO2000047225A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR030800A0 (en) * 2000-09-22 2000-10-12 Pharmalink International Limited Immunomodulatory preparation
AU2002364952B2 (en) * 2001-11-14 2008-04-10 Novavax, Inc. Mycobacterial vaccine
ATE466585T1 (de) * 2001-12-11 2010-05-15 Pasteur Institut Präparationen grampositiver bakterien zur behandlung von krankheiten mit immunfehlregulation
CU23476A1 (es) * 2004-01-29 2009-12-17 Ct Ingenieria Genetica Biotech Formulación adyuvante conteniendo una emulsión oleosa con aceite de jojoba
WO2006079989A2 (en) * 2005-01-28 2006-08-03 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
JP5713672B2 (ja) * 2007-04-12 2015-05-07 ジェニファー ライター, 結核のワクチンおよびその使用方法
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
CA2833633A1 (en) * 2011-04-20 2012-10-26 Jason Fisher Composition and method for enhancing an immune response
EP2620159A1 (de) * 2012-01-24 2013-07-31 Institut Pasteur Verbesserte Krebsbehandlung durch Immuntherapie mit BCG- oder antigenetisch ähnlichen nicht-pathogenen Mykobakterien
WO2018006939A1 (en) 2016-07-05 2018-01-11 Universidad De Zaragoza Inactivated tuberculosis vaccine
WO2020115161A1 (en) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant for use against pathogens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
DE69735294T2 (de) * 1996-03-25 2006-09-21 Medarex Inc. Spezifische monoklonale antikörper für die extrazelluläre domäne von protasta-spezifischem membranantigen
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering

Also Published As

Publication number Publication date
DK1154792T3 (da) 2007-02-12
WO2000047225A3 (en) 2000-12-14
DE60031243T2 (de) 2007-05-24
US6936260B1 (en) 2005-08-30
SE9900495D0 (sv) 1999-02-12
WO2000047225A2 (en) 2000-08-17
ES2275495T3 (es) 2007-06-16
AU769390B2 (en) 2004-01-22
EP1154792A2 (de) 2001-11-21
EP1154792B1 (de) 2006-10-11
DE60031243D1 (de) 2006-11-23
AU2803500A (en) 2000-08-29
NZ513130A (en) 2003-01-31

Similar Documents

Publication Publication Date Title
FI970799A0 (fi) Mutanttientoroksiini, joka on tehokas ei-toksinen oraalinen adjuvantti
MD1586G2 (ro) Inducere a unui răspuns citotoxic T-limfocitar
BRPI0010418B8 (pt) microorganismo de salmonella, composição de vacina e uso do referido microorganismo.
UY27465A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides
EA199900069A1 (ru) Вакцинная композиция против малярии
DE60031243D1 (de) Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant
BR0111630A (pt) Espiral para inseto
AU7814498A (en) Multivalent (in ovo) avian vaccine
KR960700746A (ko) 헬리코박터 피롤리 관련 위십이지장 질환의 치료 방법(treatment of h. pylori associated gastroduodenal disease)
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
SE9602280D0 (sv) Immunstimulerande lipidformulering
DK1024824T3 (da) Dispergerende vaccinesammensætning i fast form til oral indgivelse
ES2089923T3 (es) Composicion de vacuna subunitaria recombinante viva y procedimiento de preparacion.
ES2106809T3 (es) Agente antifungico, su preparacion y microorganismo para ello.
FI972054A0 (fi) Immunogeenisiä koostumuksia
ATE293993T1 (de) Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
EP0369216A3 (en) Pharmaceutical preparation based on ester derivatives of hecogenine, and their use in treating benign prostatic hyperplasia
ES2106032T3 (es) Vacuna para inmunizar gatos contra el desprendimiento de oocistos de toxoplasma.
ES2058451T3 (es) Un metodo para la preparacion de una composicion farmaceutica.
SE9800905D0 (sv) New therapy in glomerulonephritis
SE0100011D0 (sv) Virus vaccine formulation
AR010303A1 (es) Composicion de emulsion repelente de insectos
EA200200704A1 (ru) Ослабленные микроорганизмы для лечения инфекции
SE9402241L (sv) Inhibitor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties